Proapoptotic miltefosine nanovesicles show synergism with paclitaxel: Implications for glioblastoma multiforme therapy
Highlights • Miltefosine based proapoptotic lipid nanovesicles encapsulate paclitaxel with high efficiency. • Nanovesicles while exhibiting sustained release of paclitaxel in nasal fluid, show triggered release profile in cerebrospinal fluid. • Nanovesicles result in synergistic cytotoxic effect of...
Gespeichert in:
| Veröffentlicht in: | Cancer letters 2013-07, Vol.334 (2), p.274-283 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 283 |
|---|---|
| container_issue | 2 |
| container_start_page | 274 |
| container_title | Cancer letters |
| container_volume | 334 |
| creator | Thakur, Ankita Joshi, Nitin Shanmugam, Thanigaivel Banerjee, Rinti |
| description | Highlights • Miltefosine based proapoptotic lipid nanovesicles encapsulate paclitaxel with high efficiency. • Nanovesicles while exhibiting sustained release of paclitaxel in nasal fluid, show triggered release profile in cerebrospinal fluid. • Nanovesicles result in synergistic cytotoxic effect of paclitaxel and miltefosine and overcome drug resistance in glioblastoma cells, U-87 MG. • ATP dependent endocytosis of nanovesicles by U-87 MG cells via clathrin mediated pathway. • Upon intranasal administration, nanovesicles reach brain and are also able to cross blood brain barrier upon intravenous administration. |
| doi_str_mv | 10.1016/j.canlet.2012.08.022 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1357497856</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0304383512005101</els_id><sourcerecordid>1357497856</sourcerecordid><originalsourceid>FETCH-LOGICAL-c469t-26773cc750df676cef18b9a60ec41c37d5613217c8847975ee8a5f0cb6cce2933</originalsourceid><addsrcrecordid>eNqFkl2L1DAUhoMo7uzoPxANeLM3rUmTNK0XC7L4sbCgsO51yGROZzKmTU3SWeffm9JVYW8kF4HwnJdz8hyEXlFSUkLrd4fS6MFBKitCq5I0JamqJ2hFG1kVsm3IU7QijPCCNUycofMYD4QQwaV4js6qqmWilnKFjt-C16Mfk0_W4N66BJ2PdgA86MEfIVrjIOK49_c4ngYIOxt7fG_THo_aOJv0L3Dv8XU_Omt0sn6IuPMB75z1G6dj8r3G_eSSza894LSHoMfTC_Ss0y7Cy4d7je4-ffx-9aW4-fr5-urDTWF43aaiyj0yY6Qg266WtYGONptW1wQMp4bJragpq6g0TcNlKwVAo0VHzKY2BvKMbI0ultwx-J8TxKR6Gw04pwfwU1SUCclb2Yg6o28foQc_hSF3p2jNBaGc85niC2WCjzFAp8Zgex1OihI1e1EHtXhRsxdFGpW95LLXD-HTpoft36I_IjLwZgE67ZXeBRvV3W1OEFkaYzyfNbpcCMj_dbQQVDQWBgNbG8AktfX2fz08Dsj-hmzN_YATxH_Tqphr1O28PfPy0CrvTY5lvwFmdcDP</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1645014446</pqid></control><display><type>article</type><title>Proapoptotic miltefosine nanovesicles show synergism with paclitaxel: Implications for glioblastoma multiforme therapy</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Thakur, Ankita ; Joshi, Nitin ; Shanmugam, Thanigaivel ; Banerjee, Rinti</creator><creatorcontrib>Thakur, Ankita ; Joshi, Nitin ; Shanmugam, Thanigaivel ; Banerjee, Rinti</creatorcontrib><description>Highlights • Miltefosine based proapoptotic lipid nanovesicles encapsulate paclitaxel with high efficiency. • Nanovesicles while exhibiting sustained release of paclitaxel in nasal fluid, show triggered release profile in cerebrospinal fluid. • Nanovesicles result in synergistic cytotoxic effect of paclitaxel and miltefosine and overcome drug resistance in glioblastoma cells, U-87 MG. • ATP dependent endocytosis of nanovesicles by U-87 MG cells via clathrin mediated pathway. • Upon intranasal administration, nanovesicles reach brain and are also able to cross blood brain barrier upon intravenous administration.</description><identifier>ISSN: 0304-3835</identifier><identifier>EISSN: 1872-7980</identifier><identifier>DOI: 10.1016/j.canlet.2012.08.022</identifier><identifier>PMID: 22935677</identifier><language>eng</language><publisher>Ireland: Elsevier Ireland Ltd</publisher><subject>Animals ; anticarcinogenic activity ; Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics ; Antineoplastic Combined Chemotherapy Protocols - pharmacology ; apoptosis ; Blood brain barrier ; Blood-Brain Barrier - metabolism ; brain ; Brain Neoplasms - drug therapy ; Brain Neoplasms - pathology ; Cancer ; Cell Line, Tumor ; cerebrospinal fluid ; clathrin ; Drug delivery systems ; Drug Synergism ; Drug therapy ; encapsulation ; Female ; gene overexpression ; genes ; Glioblastoma - drug therapy ; Glioblastoma - metabolism ; Glioblastoma - pathology ; Glioblastoma multiforme ; Hematology, Oncology and Palliative Medicine ; Humans ; Intranasal ; intranasal administration ; Kinases ; Lipid nanovesicles ; Male ; Miltefosine ; multiple drug resistance ; Nanostructures - administration & dosage ; Nanostructures - chemistry ; Nose ; Paclitaxel ; Paclitaxel - administration & dosage ; Paclitaxel - chemistry ; Paclitaxel - pharmacokinetics ; Paclitaxel - pharmacology ; Phosphorylcholine - administration & dosage ; Phosphorylcholine - analogs & derivatives ; Phosphorylcholine - chemistry ; Phosphorylcholine - pharmacokinetics ; Phosphorylcholine - pharmacology ; Rats ; Rats, Wistar ; synergism ; therapeutics ; zeta potential</subject><ispartof>Cancer letters, 2013-07, Vol.334 (2), p.274-283</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2012 Elsevier Ireland Ltd</rights><rights>Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Jul 1, 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c469t-26773cc750df676cef18b9a60ec41c37d5613217c8847975ee8a5f0cb6cce2933</citedby><cites>FETCH-LOGICAL-c469t-26773cc750df676cef18b9a60ec41c37d5613217c8847975ee8a5f0cb6cce2933</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0304383512005101$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22935677$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Thakur, Ankita</creatorcontrib><creatorcontrib>Joshi, Nitin</creatorcontrib><creatorcontrib>Shanmugam, Thanigaivel</creatorcontrib><creatorcontrib>Banerjee, Rinti</creatorcontrib><title>Proapoptotic miltefosine nanovesicles show synergism with paclitaxel: Implications for glioblastoma multiforme therapy</title><title>Cancer letters</title><addtitle>Cancer Lett</addtitle><description>Highlights • Miltefosine based proapoptotic lipid nanovesicles encapsulate paclitaxel with high efficiency. • Nanovesicles while exhibiting sustained release of paclitaxel in nasal fluid, show triggered release profile in cerebrospinal fluid. • Nanovesicles result in synergistic cytotoxic effect of paclitaxel and miltefosine and overcome drug resistance in glioblastoma cells, U-87 MG. • ATP dependent endocytosis of nanovesicles by U-87 MG cells via clathrin mediated pathway. • Upon intranasal administration, nanovesicles reach brain and are also able to cross blood brain barrier upon intravenous administration.</description><subject>Animals</subject><subject>anticarcinogenic activity</subject><subject>Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics</subject><subject>Antineoplastic Combined Chemotherapy Protocols - pharmacology</subject><subject>apoptosis</subject><subject>Blood brain barrier</subject><subject>Blood-Brain Barrier - metabolism</subject><subject>brain</subject><subject>Brain Neoplasms - drug therapy</subject><subject>Brain Neoplasms - pathology</subject><subject>Cancer</subject><subject>Cell Line, Tumor</subject><subject>cerebrospinal fluid</subject><subject>clathrin</subject><subject>Drug delivery systems</subject><subject>Drug Synergism</subject><subject>Drug therapy</subject><subject>encapsulation</subject><subject>Female</subject><subject>gene overexpression</subject><subject>genes</subject><subject>Glioblastoma - drug therapy</subject><subject>Glioblastoma - metabolism</subject><subject>Glioblastoma - pathology</subject><subject>Glioblastoma multiforme</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Intranasal</subject><subject>intranasal administration</subject><subject>Kinases</subject><subject>Lipid nanovesicles</subject><subject>Male</subject><subject>Miltefosine</subject><subject>multiple drug resistance</subject><subject>Nanostructures - administration & dosage</subject><subject>Nanostructures - chemistry</subject><subject>Nose</subject><subject>Paclitaxel</subject><subject>Paclitaxel - administration & dosage</subject><subject>Paclitaxel - chemistry</subject><subject>Paclitaxel - pharmacokinetics</subject><subject>Paclitaxel - pharmacology</subject><subject>Phosphorylcholine - administration & dosage</subject><subject>Phosphorylcholine - analogs & derivatives</subject><subject>Phosphorylcholine - chemistry</subject><subject>Phosphorylcholine - pharmacokinetics</subject><subject>Phosphorylcholine - pharmacology</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>synergism</subject><subject>therapeutics</subject><subject>zeta potential</subject><issn>0304-3835</issn><issn>1872-7980</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkl2L1DAUhoMo7uzoPxANeLM3rUmTNK0XC7L4sbCgsO51yGROZzKmTU3SWeffm9JVYW8kF4HwnJdz8hyEXlFSUkLrd4fS6MFBKitCq5I0JamqJ2hFG1kVsm3IU7QijPCCNUycofMYD4QQwaV4js6qqmWilnKFjt-C16Mfk0_W4N66BJ2PdgA86MEfIVrjIOK49_c4ngYIOxt7fG_THo_aOJv0L3Dv8XU_Omt0sn6IuPMB75z1G6dj8r3G_eSSza894LSHoMfTC_Ss0y7Cy4d7je4-ffx-9aW4-fr5-urDTWF43aaiyj0yY6Qg266WtYGONptW1wQMp4bJragpq6g0TcNlKwVAo0VHzKY2BvKMbI0ultwx-J8TxKR6Gw04pwfwU1SUCclb2Yg6o28foQc_hSF3p2jNBaGc85niC2WCjzFAp8Zgex1OihI1e1EHtXhRsxdFGpW95LLXD-HTpoft36I_IjLwZgE67ZXeBRvV3W1OEFkaYzyfNbpcCMj_dbQQVDQWBgNbG8AktfX2fz08Dsj-hmzN_YATxH_Tqphr1O28PfPy0CrvTY5lvwFmdcDP</recordid><startdate>20130701</startdate><enddate>20130701</enddate><creator>Thakur, Ankita</creator><creator>Joshi, Nitin</creator><creator>Shanmugam, Thanigaivel</creator><creator>Banerjee, Rinti</creator><general>Elsevier Ireland Ltd</general><general>Elsevier Limited</general><scope>FBQ</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20130701</creationdate><title>Proapoptotic miltefosine nanovesicles show synergism with paclitaxel: Implications for glioblastoma multiforme therapy</title><author>Thakur, Ankita ; Joshi, Nitin ; Shanmugam, Thanigaivel ; Banerjee, Rinti</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c469t-26773cc750df676cef18b9a60ec41c37d5613217c8847975ee8a5f0cb6cce2933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Animals</topic><topic>anticarcinogenic activity</topic><topic>Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics</topic><topic>Antineoplastic Combined Chemotherapy Protocols - pharmacology</topic><topic>apoptosis</topic><topic>Blood brain barrier</topic><topic>Blood-Brain Barrier - metabolism</topic><topic>brain</topic><topic>Brain Neoplasms - drug therapy</topic><topic>Brain Neoplasms - pathology</topic><topic>Cancer</topic><topic>Cell Line, Tumor</topic><topic>cerebrospinal fluid</topic><topic>clathrin</topic><topic>Drug delivery systems</topic><topic>Drug Synergism</topic><topic>Drug therapy</topic><topic>encapsulation</topic><topic>Female</topic><topic>gene overexpression</topic><topic>genes</topic><topic>Glioblastoma - drug therapy</topic><topic>Glioblastoma - metabolism</topic><topic>Glioblastoma - pathology</topic><topic>Glioblastoma multiforme</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Intranasal</topic><topic>intranasal administration</topic><topic>Kinases</topic><topic>Lipid nanovesicles</topic><topic>Male</topic><topic>Miltefosine</topic><topic>multiple drug resistance</topic><topic>Nanostructures - administration & dosage</topic><topic>Nanostructures - chemistry</topic><topic>Nose</topic><topic>Paclitaxel</topic><topic>Paclitaxel - administration & dosage</topic><topic>Paclitaxel - chemistry</topic><topic>Paclitaxel - pharmacokinetics</topic><topic>Paclitaxel - pharmacology</topic><topic>Phosphorylcholine - administration & dosage</topic><topic>Phosphorylcholine - analogs & derivatives</topic><topic>Phosphorylcholine - chemistry</topic><topic>Phosphorylcholine - pharmacokinetics</topic><topic>Phosphorylcholine - pharmacology</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>synergism</topic><topic>therapeutics</topic><topic>zeta potential</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Thakur, Ankita</creatorcontrib><creatorcontrib>Joshi, Nitin</creatorcontrib><creatorcontrib>Shanmugam, Thanigaivel</creatorcontrib><creatorcontrib>Banerjee, Rinti</creatorcontrib><collection>AGRIS</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Thakur, Ankita</au><au>Joshi, Nitin</au><au>Shanmugam, Thanigaivel</au><au>Banerjee, Rinti</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Proapoptotic miltefosine nanovesicles show synergism with paclitaxel: Implications for glioblastoma multiforme therapy</atitle><jtitle>Cancer letters</jtitle><addtitle>Cancer Lett</addtitle><date>2013-07-01</date><risdate>2013</risdate><volume>334</volume><issue>2</issue><spage>274</spage><epage>283</epage><pages>274-283</pages><issn>0304-3835</issn><eissn>1872-7980</eissn><abstract>Highlights • Miltefosine based proapoptotic lipid nanovesicles encapsulate paclitaxel with high efficiency. • Nanovesicles while exhibiting sustained release of paclitaxel in nasal fluid, show triggered release profile in cerebrospinal fluid. • Nanovesicles result in synergistic cytotoxic effect of paclitaxel and miltefosine and overcome drug resistance in glioblastoma cells, U-87 MG. • ATP dependent endocytosis of nanovesicles by U-87 MG cells via clathrin mediated pathway. • Upon intranasal administration, nanovesicles reach brain and are also able to cross blood brain barrier upon intravenous administration.</abstract><cop>Ireland</cop><pub>Elsevier Ireland Ltd</pub><pmid>22935677</pmid><doi>10.1016/j.canlet.2012.08.022</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0304-3835 |
| ispartof | Cancer letters, 2013-07, Vol.334 (2), p.274-283 |
| issn | 0304-3835 1872-7980 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1357497856 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Animals anticarcinogenic activity Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics Antineoplastic Combined Chemotherapy Protocols - pharmacology apoptosis Blood brain barrier Blood-Brain Barrier - metabolism brain Brain Neoplasms - drug therapy Brain Neoplasms - pathology Cancer Cell Line, Tumor cerebrospinal fluid clathrin Drug delivery systems Drug Synergism Drug therapy encapsulation Female gene overexpression genes Glioblastoma - drug therapy Glioblastoma - metabolism Glioblastoma - pathology Glioblastoma multiforme Hematology, Oncology and Palliative Medicine Humans Intranasal intranasal administration Kinases Lipid nanovesicles Male Miltefosine multiple drug resistance Nanostructures - administration & dosage Nanostructures - chemistry Nose Paclitaxel Paclitaxel - administration & dosage Paclitaxel - chemistry Paclitaxel - pharmacokinetics Paclitaxel - pharmacology Phosphorylcholine - administration & dosage Phosphorylcholine - analogs & derivatives Phosphorylcholine - chemistry Phosphorylcholine - pharmacokinetics Phosphorylcholine - pharmacology Rats Rats, Wistar synergism therapeutics zeta potential |
| title | Proapoptotic miltefosine nanovesicles show synergism with paclitaxel: Implications for glioblastoma multiforme therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T08%3A23%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Proapoptotic%20miltefosine%20nanovesicles%20show%20synergism%20with%20paclitaxel:%20Implications%20for%20glioblastoma%20multiforme%20therapy&rft.jtitle=Cancer%20letters&rft.au=Thakur,%20Ankita&rft.date=2013-07-01&rft.volume=334&rft.issue=2&rft.spage=274&rft.epage=283&rft.pages=274-283&rft.issn=0304-3835&rft.eissn=1872-7980&rft_id=info:doi/10.1016/j.canlet.2012.08.022&rft_dat=%3Cproquest_cross%3E1357497856%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1645014446&rft_id=info:pmid/22935677&rft_els_id=S0304383512005101&rfr_iscdi=true |